Val-Ala-PABC-Exatecan (trifluoroacetate)

Val-Ala-PABC-Exatecan trifluoroacetate is a Drug-Linker Conjugates for ADC, consiting of a cleavable Tesirine linker (Val-Ala-PABC) and Exatecan (topoisomerase I inhibitor, HY-13631) . Val-Ala-PABC-Exatecan trifluoroacetate can be used for ADC molecues synthesis, such as Mal-PEGn-amide-va-Exatecan[1].

Product Specifications

CAS Number

[2928571-45-1]

UNSPSC

12352203

Target

Drug-Linker Conjugates for ADC; Topoisomerase

Type

ADC Related

Related Pathways

Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/val-ala-pabc-exatecan-trifluoroacetate.html

Purity

98.39

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

CC[C@]1(C(OCC2=C1C=C3C4=NC5=CC(F)=C(C6=C5C([C@H](CC6)NC(OCC7=CC=C(C=C7)NC([C@@H](NC([C@H](C(C)C)N)=O)C)=O)=O)=C4CN3C2=O)C)=O)O.OC(C(F)(F)F)=O

Molecular Formula

C42H44F4N6O10

Molecular Weight

868.83

References & Citations

[1]Cheng X, et al. MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity. Mol Cancer Ther. 2018 Dec;17 (12) :2665-2675.